Diagnosis and evaluation of prognosis of myelofibrosis: a British Society for Haematology Guideline

Diagnosis and evaluation of prognosis of myelofibrosis: a British Society for Haematology Guideline

This document represents an update of the British Society for Haematology (BSH) guideline on myelofibrosis (MF) first published in 2012 and updated in 2015.1 This guideline aims to provide healthcare professionals with clear guidance on the diagnosis and prognostic evaluation of primary myelofibrosi...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak:	McLornan, DP, Godfrey, AL, Green, A, Frewin, R, Arami, S, Brady, J, Butt, NM, Cargo, C, Ewing, J, Francis, S, Garg, M, Harrison, C, Innes, A, Khan, A, Knapper, S, Lambert, J, Mead, A, McGregor, A, Neelakantan, P, Psaila, B, Somervaille, TCP, Woodley, C, Nangalia, J, Cross, NCP, McMullin, MF
Beste egile batzuk:	BSH Committee
Formatua:	Journal article
Hizkuntza:	English
Argitaratua:	Wiley 2023

Antzeko izenburuak

A guideline for the diagnosis and management of polycythaemia vera. A British Society for haematology guideline
nork: McMullin, M, et al.
Argitaratua: (2018)

A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis
nork: McMullin, M, et al.
Argitaratua: (2018)

Allogeneic stem cell transplantation for myelofibrosis in 2012.
nork: McLornan, D, et al.
Argitaratua: (2012)

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.
nork: Reilly, J, et al.
Argitaratua: (2014)

Guideline for the diagnosis and management of myelofibrosis.
nork: Reilly, J, et al.
Argitaratua: (2012)

Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date
nork: Bassiony S, et al.
Argitaratua: (2020-09-01)

MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic
nork: Verstovsek, S, et al.
Argitaratua: (2021)

P991: IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
nork: P. Harrington, et al.
Argitaratua: (2022-06-01)

A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study
nork: Mead, AJ, et al.
Argitaratua: (2022)

Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm
nork: Salisbury, RA, et al.
Argitaratua: (2021)

Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012
nork: Mclornan, D, et al.
Argitaratua: (2012)

Symptomatic benefit of momelotinib in patients with myelofibrosis: results from the SIMPLIFY phase III studies
nork: Mesa, RA, et al.
Argitaratua: (2023)

Mutational spectrum defines primary and secondary myelofibrosis
nork: Ken I. Mills, et al.
Argitaratua: (2014-01-01)

Guideline for the diagnosis and management of myelofibrosis
nork: Reilly, J, et al.
Argitaratua: (2012)

Use of JAK inhibitors in the management of myelofibrosis: A revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
nork: Reilly, J, et al.
Argitaratua: (2014)

Low-dose thalidomide in myelofibrosis
nork: Robert Weinkove, et al.
Argitaratua: (2008-07-01)

A retrospective real world evidence study to review the current treatment pathways for myelofibrosis from across the United Kingdom (the REALISM UK study)
nork: Mead, A, et al.
Argitaratua: (2019)

Guideline for the investigation and management of eosinophilia
nork: Butt, N, et al.
Argitaratua: (2017)

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
nork: Donal P. McLornan, et al.
Argitaratua: (2019-04-01)

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis
nork: Stephen T. Oh, et al.
Argitaratua: (2024-02-01)

Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies
nork: Ruben A. Mesa, et al.
Argitaratua: (2023-05-01)

Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study
nork: Ruben A. Mesa, et al.
Argitaratua: (2023-11-01)

Feasibility of recruitment of patients withMyeloproliferative Neoplasms into the TAPfunded TAMARIN study
nork: Harrison, C, et al.
Argitaratua: (2018)

Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial
nork: McIlroy, G, et al.
Argitaratua: (2025)

Equivalence of BCSH and WHO diagnostic criteria for ET
nork: Harrison, C, et al.
Argitaratua: (2016)

The soldier and the post-conflict state
nork: McMullin, J, et al.
Argitaratua: (2006)

The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders
nork: Cross, NCP, et al.
Argitaratua: (2021)

Practical management of patients with myelofibrosis receiving ruxolitinib.
nork: Harrison, C, et al.
Argitaratua: (2013)

Ruxolitinib induces changes in histone modification status in patients entered into the MAJIC clinical trial
nork: McPherson, S, et al.
Argitaratua: (2018)

A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study
nork: Adam J. Mead, et al.
Argitaratua: (2022-03-01)

Intravesical recurrence of chromophobe renal cell carcinoma
nork: Niall P. Kelly, et al.
Argitaratua: (2023-09-01)

A single-cell approach to unraveling abnormal megakaryocyte differentiation and function in myelofibrosis
nork: Psaila, B, et al.
Argitaratua: (2017)

In utero origin of myelofibrosis presenting in adult monozygotic twins
nork: Sousos, N, et al.
Argitaratua: (2022)

Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial
nork: Graham McIlroy, et al.
Argitaratua: (2025-01-01)

P1068: RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS
nork: A. Vannucchi, et al.
Argitaratua: (2022-06-01)

Spliceosome mutations are common in MPN-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
nork: Chowdhury, O, et al.
Argitaratua: (2018)

Rapid emergence of chronic lymphocytic leukemia during JAK2 inhibitor therapy in a patient with myelofibrosis
nork: Sousos, N, et al.
Argitaratua: (2020)

Modification of the histone landscape with JAK inhibition in myeloproliferative neoplasms
nork: Greenfield, G, et al.
Argitaratua: (2020)

S197: NAVITOCLAX PLUS RUXOLITINIB IN JAK INHIBITOR-NAÏVE PATIENTS WITH MYELOFIBROSIS: PRELIMINARY SAFETY AND EFFICACY IN A MULTICENTER, OPEN-LABEL PHASE 2 STUDY
nork: F. Passamonti, et al.
Argitaratua: (2022-06-01)

The UK Myeloproliferative Neoplasm Registry for Myelofibrosis (UK-MPN-MF registry)
nork: Butt, N, et al.
Argitaratua: (2019)